The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global in-vitro diagnostics enzymes market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 8% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
In-vitro diagnostics are tests that are done on certain samples, including blood and tissue derived from the human body. They involve the use of assays and reagents to diagnose the medical condition in patients. They assist in providing necessary information pertaining to the diagnosis, screening, and monitoring of the ailment for the treatment and prevention of the same. Enzymes are widely employed in these diagnostic solutions for the detection of an extensive range of illnesses due to their excellent biocatalytic properties. Various enzymes, such as gelatinase-B, alanine transaminase, creatine kinase, acid phosphatase, aspartate transaminase and lactate dehydrogenase, are used as preferred biomarkers for the diagnosis of numerous ailments, including renal disease, cancer and rheumatoid arthritis.
The global market is primarily driven by the increasing demand for effective infectious disease diagnosis. This has led to the continual developments in the polymerase chain reaction (PCR) and its widespread applicability across the healthcare sector. PCR enables the easy detection of various organisms with improved precision and sensitivity, thereby providing an impetus to the market growth. Moreover, the development of enzyme biosensors has resulted in a considerable rise in enzyme utility for clinical diagnosis of certain medical conditions, such as tuberculosis, atypical pneumonia, streptococcal pharyngitis and ulcerative urogenital infections. This, in turn, is creating a positive outlook for the market. The widespread utilization of in-vitro diagnostics for the diagnosis of the coronavirus disease (COVID-19) is acting as another major growth-inducing factor. Apart from this, the rising number of cancer cases across the globe has led to the increasing demand for efficient diagnostic solutions that require the utilization of enzymes for histopathology of biopsy samples. Some of the other factors contributing to the market growth include continual improvements in the healthcare infrastructure and the rising investments in research and development (R&D) activities.
IMARC Group provides an analysis of the key trends in each sub-segment of the global in-vitro diagnostics enzymes market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on enzyme type, disease type, technology type and end use.
Breakup by Enzyme Type:
Breakup by Disease Type:
Breakup by Technology Type:
Breakup by End Use:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Advanced Enzymes Technologies Ltd., Affymetrix (Thermo Fisher Scientific), Amano Enzyme Inc., American Laboratories Inc., Amicogen Inc., BBI Solutions, Biocatalysts Limited (Brain AG), Codexis Inc., Dyadic International Inc., F. Hoffmann-La Roche AG and Merck KGaA.
|Base Year of the Analysis||2020|
|Segment Coverage||Enzyme Type, Disease Type, Technology Type, End Use, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Advanced Enzymes Technologies Ltd., Affymetrix (Thermo Fisher Scientific), Amano Enzyme Inc., American Laboratories Inc., Amicogen Inc., BBI Solutions, Biocatalysts Limited (Brain AG), Codexis Inc., Dyadic International Inc., F. Hoffmann-La Roche AG and Merck KGaA|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at